These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1735771)

  • 1. Intrathecal synthesis of soluble class I antigens in multiple sclerosis.
    Alvarez-Cermeño JC; Villar LM; Nocito M; Bootello A; González-Porqué P
    J Neuroimmunol; 1992 Jan; 36(1):77-9. PubMed ID: 1735771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Paolino E; Tola MR; Granieri E; Baricordi OR
    Mult Scler; 2006 Feb; 12(1):2-12. PubMed ID: 16459714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients.
    Filaci G; Contini P; Brenci S; Gazzola P; Lanza L; Scudeletti M; Indiveri F; Mancardi GL; Puppo F
    Hum Immunol; 1997 Apr; 54(1):54-62. PubMed ID: 9154458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble HLA class I and class II antigens in patients with multiple sclerosis.
    Ott M; Seidl C; Westhoff U; Stecker K; Seifried E; Fischer PA; Grosse-Wilde H
    Tissue Antigens; 1998 Mar; 51(3):301-4. PubMed ID: 9550332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.
    Fainardi E; Rizzo R; Melchiorri L; Vaghi L; Castellazzi M; Marzola A; Govoni V; Paolino E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2003 Sep; 142(1-2):149-58. PubMed ID: 14512174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules.
    Fainardi E; Granieri E; Tola MR; Melchiorri L; Vaghi L; Rizzo R; Castellazzi M; Ceruti S; Paolino E; Baricordi OR
    J Neuroimmunol; 2002 Dec; 133(1-2):151-9. PubMed ID: 12446018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation.
    Morandi F; Venturi C; Rizzo R; Castellazzi M; Baldi E; Caniatti ML; Tola MR; Granieri E; Fainardi E; Uccelli A; Pistoia V
    J Neuroimmune Pharmacol; 2013 Sep; 8(4):944-55. PubMed ID: 23625177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble class 1 antigens (sHLA) in CSF and serum of patients with HIV infection.
    Alvarez-Cermeño JC; Casado C; Villar LM; Ferreira A; Varela JM; Dominguez M; Bootello A; Najera R; Gonzalez-Porque P
    Acta Neurol Scand; 1990 Jul; 82(1):14-6. PubMed ID: 2239130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of soluble human leukocyte antigen-G molecules in multiple sclerosis.
    Fainardi E; Rizzo R; Castellazzi M; Stignani M; Granieri E; Baricordi OR
    Hum Immunol; 2009 Dec; 70(12):981-7. PubMed ID: 19651179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Caniatti ML; Baldi E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2007 Dec; 192(1-2):219-25. PubMed ID: 17997167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Tamborino C; Paolino E; Tola MR; Granieri E; Baricordi OR
    Mult Scler; 2008 May; 14(4):446-54. PubMed ID: 18208868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrathecal synthesis of soluble class I antigens (sHLA) in patients with HIV infection and tuberculous meningitis.
    Alvarez-Cermeño JC; Varela JM; Villar LM; Casado C; Dominguez M; Roy G; Bootello A; Gonzalez-Porque P
    J Neurol Sci; 1990 Dec; 100(1-2):152-4. PubMed ID: 2089132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble class I antigens in serum and CSF of patients with varicella-zoster virus meningitis.
    Alvarez-Cermeño J; Echevarría JM; Villar LM; Lázaro I; Bootello A; González-Porque P
    J Neurol Neurosurg Psychiatry; 1989 Oct; 52(10):1194-6. PubMed ID: 2552020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity.
    Wiendl H; Feger U; Mittelbronn M; Jack C; Schreiner B; Stadelmann C; Antel J; Brueck W; Meyermann R; Bar-Or A; Kieseier BC; Weller M
    Brain; 2005 Nov; 128(Pt 11):2689-704. PubMed ID: 16123145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble HLA in human body fluids.
    Aultman D; Adamashvili I; Yaturu K; Langford M; Gelder F; Gautreaux M; Ghali GE; McDonald J
    Hum Immunol; 1999 Mar; 60(3):239-44. PubMed ID: 10321960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis.
    Rizzo R; Pietrobon S; Mazzoni E; Bortolotti D; Martini F; Castellazzi M; Casetta I; Fainardi E; Di Luca D; Granieri E; Tognon M;
    J Transl Med; 2016 Jul; 14(1):216. PubMed ID: 27443345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentration of soluble adhesion molecules (sVCAM-1, sICAM-1 and sL-selectin) in the cerebrospinal fluid and serum of patients with multiple sclerosis and systemic lupus erythematosus with central nervous involvement.
    Baraczka K; Nékám K; Pozsonyi T; Jakab L; Szongoth M; Seszták M
    Neuroimmunomodulation; 2001; 9(1):49-54. PubMed ID: 11435752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
    Mouzaki A; Rodi M; Dimisianos N; Emmanuil A; Kalavrizioti D; Lagoudaki R; Grigoriadis NC; Papathanasopoulos P
    PLoS One; 2015; 10(8):e0135434. PubMed ID: 26317430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.
    Sharief MK; Hentges R; Ciardi M; Thompson EJ
    J Neurol; 1993 Jan; 240(1):46-50. PubMed ID: 8423463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system.
    Trojano M; Avolio C; Ruggieri M; De Robertis F; Giuliani F; Paolicelli D; Livrea P
    Mult Scler; 1998 Feb; 4(1):39-44. PubMed ID: 9532592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.